ZDHHC20 and cancer: Knowing that DHHC20 ablation would sensitize cancer cells to small-molecule TKI and that MDA-MB-231 cells express unusually high levels of wild-type EGFR, we treated these cells with gefitinib after DHHC20 disruption and found an elevated gefitinib-induced cell death in DHHC20 shRNA expressing cells compared to control shRNA expressing cells [21].